Eterna Therapeutics Inc
$ 0.32
-10.28%
13 Feb - close price
- Market Cap 2,857,900 USD
- Current Price $ 0.32
- High / Low $ 0.35 / 0.32
- Stock P/E 0.01
- Book Value 0.46
- EPS 56.32
- Next Earning Report 2026-03-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.89 %
- ROE -22.64 %
- 52 Week High 5.55
- 52 Week Low 0.27
About
Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
Analyst Target Price
$3.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-13 | 2025-05-07 | 2025-03-12 | 2023-11-13 | 2023-08-11 | 2023-05-11 | 2023-03-20 | 2022-11-14 | 2022-08-11 | 2022-04-15 | 2021-12-31 |
| Reported EPS | -0.15 | -0.61 | -2.31 | -0.15 | -1.0335 | -0.8516 | -1.24 | -1.24 | -2.49 | -1.2 | -3.2 | -3.2 |
| Estimated EPS | 0 | 0 | 0 | 0 | None | None | -0.14 | -0.14 | -2.2 | -2.6 | -2.5 | -37.5 |
| Surprise | -0.15 | -0.61 | -2.31 | -0.15 | 0 | 0 | -1.1 | -1.1 | -0.29 | 1.4 | -0.7 | 34.3 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | -785.7143% | -785.7143% | -13.1818% | 53.8462% | -28% | 91.4667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ERNA
2026-02-12 02:02:52
Ernexa Therapeutics (ERNA) has secured approximately $10.5 million in gross proceeds through a public offering of common stock, pre-funded warrants, and common warrants. The company entered into a placement agency agreement with Brookline Capital Markets, securities purchase agreements with investors, and a warrant agent agreement with Computershare. These funds will support development programs, working capital, and general corporate purposes.
2026-02-07 12:59:05
Ernexa Therapeutics Inc. announced the pricing of a best-efforts registered public offering totaling $10.5 million. The offering includes 21,000,000 shares of common stock (or equivalents) and warrants to purchase an equal number of shares, priced at $0.50 per share and accompanying warrant. The net proceeds will fund development programs, working capital, and general corporate purposes, with potential additional gross proceeds of $14.3 million if warrants are fully exercised.
2026-02-06 15:59:07
Ernexa Therapeutics Inc. has priced a public offering of 21 million shares and accompanying warrants at $0.50 per share, aiming to raise $10.5 million in gross proceeds. The offering includes warrants exercisable at $0.68 per share, which could bring an additional $14.3 million if fully exercised. The net proceeds are intended for development programs, working capital, and general corporate purposes, crucial for advancing its cell therapy platform for cancer and autoimmune diseases.
2026-02-06 14:59:07
Ernexa Therapeutics Inc. announced the pricing of a best-efforts public offering to raise approximately $10.5 million through the sale of 21 million shares of common stock and accompanying warrants at $0.50 per share. The warrants, exercisable at $0.68, could generate an additional $14.3 million if fully exercised. The proceeds will be used to advance its development programs, particularly for lead product ERNA-101 for advanced cancer, and for general corporate purposes.
2026-02-06 14:27:51
Ernexa Therapeutics Inc. announced the pricing of a public offering of 21 million shares of common stock and warrants at $0.50 per share, aiming to raise approximately $10.5 million. The warrants are exercisable at $0.68 and could generate an additional $14.3 million if fully exercised. The proceeds will fund the company's development programs, especially for its lead cancer therapy ERNA-101, and for general corporate purposes.
2026-02-06 13:59:07
Ernexa Therapeutics (Nasdaq: ERNA) announced the pricing of a best-efforts public offering of 21,000,000 common shares and accompanying warrants at $0.50 per unit, aiming to raise approximately $10.5 million. The warrants have an exercise price of $0.68 and expire on the earlier of five years or 180 days after the public release of Phase 1 ERNA-101 clinical data. Proceeds from the offering, expected to close around February 10, 2026, will be used for program advancement, working capital, and general corporate purposes.
